HSYA对人晶状体上皮细胞系SRA01/04生物学特性的影响

doi:10.3760/cma.j.issn.1007-1245.2024.09.016

摘要/Abstract

摘要：

目的　探讨羟基红花黄色素A（HSYA）对重组人表皮生长因子（rhEGF）诱导的人晶状体上皮细胞系SRA01/04（HLEC-SRA01/04）增殖、迁移及上皮-间质转化（EMT）的影响。方法　研究时间为2022年6月至2023年9月。不同浓度HSYA溶液处理rhEGF诱导的HLEC-SRA01/04不同时长，四甲基偶氮唑蓝（MTT）比色法检测各组细胞的增殖状态并计算半数抑制浓度值（IC50）。细胞划痕实验与Transwell小室测定不同浓度组细胞的迁移能力。逆转录荧光定量聚合链式反应法（RT-qPCR）与蛋白印迹法（Western Blot）测定不同浓度组细胞内增殖细胞核抗原（PCNA）及EMT标记物波形蛋白（Vimentin）的mRNA表达水平与蛋白含量。计量资料采用t检验。结果　MTT实验结果示：选取20、40、60、80、100 μmol/L的HSYA溶液处理5 μg/L rhEGF诱导人晶状体上皮细胞24 h后，增殖抑制率分别为（12.1±0.6）%、（19.0±3.8）%、（31.5±2.2）%、（53.7±0.4）%、（70.8±0.3）%，IC50值为（76.520±0.954）μmol/L，48 h增殖抑制率分别为（14.3±3.7）%、（27.4±3.1）%、（42.6±2.7）%、（59.2±2.2）%、（81.0±1.0）%，IC50值为（66.094±2.508）μmol/L，呈明显剂量依赖性。细胞划痕实验结果显示：空白组及0、20、40、70、100 μmol/L组的24 h细胞迁移率分别为（46.9±1.8）%、（90.0±1.5）%、（88.4±2.1）%、（43.3±6.6）%、（31.5±16.2）%、（5.82±5.2）%，48 h细胞迁移率分别为（81.1±2.3）%、100%、（95.5±0.1）%、（72.6±3.5）%、（58.5±6.1）%、（37.4±7.1）%。Transwell小室实验结果显示：空白组及0、20、40、70、100 μmol/L组的细胞数分别为（171.667±20.407）个、（290.222±24.135）个、（198.667±16.826）个、（161.222±5.981）个、（134.111±6.850）个、（67.444±7.351）个，HSYA对rhEGF诱导人晶状体上皮细胞迁移的抑制呈明显浓度依赖性。RT-qPCR法及Western Blot法结果示：HSYA可明显下调rhEGF诱导的人晶状体上皮细胞内PCNA、Vimentin及mRNA表达水平，呈剂量依赖性。结论　HSYA可明显抑制rhEGF诱导的HLEC-SRA01/04增殖、迁移及EMT，可能成为预防后发性白内障的潜在药物。

关键词:

后发性白内障, 羟基红花黄色素A, 重组人表皮生长因子, 晶状体上皮细胞, 上皮-间质转化

Abstract:

Objective　To explore the effects of hydroxysafflor yellow A (HSYA) on the proliferation, migration, and epithelial-mesenchymal transition (EMT) of human lens epithelial cell line SRA01/04 (HLEC-SRA01/04) induced by recombinant human epidermal growth factor (rhEGF). Methods　This study was from June 2022 to September 2023. The HLEC-SRA01/04 induced by rhEGF were treated with different concentrations of HSYA solution for different durations. The proliferation status of the cells of each group was detected by the MTT assay, and the IC50 value was calculated. The cell scratch test and Transwell chamber were used to measure the migration ability of the cells in different concentration groups. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western Blot were adopted to determine the mRNA and protein expression levels of proliferating cell nuclear antigen (PCNA) and vimentin involved in EMT in the cells of different concentration groups. The measurement data were compared by the t test. Results　The MTT assay results showed that the proliferation inhibition rates were (12.1±0.6)%, (19.0±3.8)%, (31.5±2.2)%, (53.7±0.4)%, and (70.8±0.3)%, respectively, and the IC50 value was (76.520±0.954) μmol/L after treating HLECs induced by 5 μg/L rhEGF with the HSYA solution of 20, 40, 60, 80, and 100 μmol/L for 24 h; the proliferation inhibition rates were (14.3±3.7)%, (27.4±3.1)%, (42.6±2.7)%, (59.2±2.2)%, and (81.0±1.0)% , respectively, and the IC50 value was (66.094±2.508) μmol/L after treating HLECs induced by 5 μg/L rhEGF with the HSYA solution of 20, 40, 60, 80, and 100 μmol/L for 48 h, indicating significant dose-dependent effects. The cell scratch test results showed that the 24 h cell migration rates of the blank group and the 0, 20, 40, 70, and 100 μmol/L groups were (46.9±1.8)%, (90.0±1.5)%, (88.4±2.1)%, (43.3±6.6)%, (31.5±16.2)%, and (5.82±5.2)%, and the 48 h cell migration rates were (81.1±2.3)%, 100%, (95.5±0.1)%, (72.6±3.5)%, (58.5±6.1)%, and (37.4±7.1)%, respectively. The Transwell chamber results showed that the numbers of cells in the blank group and the 0, 20, 40, 70, and 100 μmol/L groups were (171.667±20.407), (290.222±24.135), (198.667±16.826), (161.222±5.981), (134.111±6.850), and (67.444±7.351), respectively; HSYA inhibited the migration of HLECs induced by rhEGF in a concentration-dependent manner. The RT-qPCR and Western Blot results proved that HSYA significantly down-regulated the mRNA and protein expressions of PCNA and Vimentin in HLECs induced by rhEGF in a dose-dependent manner. Conclusion　HSYA remarkably inhibits the proliferation, migration, and EMT of HLEC-SRA01/04 induced by rhEGF, serving as a promising drug for preventing posterior capsular opacification.

Key words:

Posterior capsular opacification, Hydroxysafflor yellow A, Recombinant human epidermal growth factor, Lens epithelial cells, Epithelial-mesenchymal transition

李诗怡王康黄菊张澳张培培谢迎宾.

HSYA对人晶状体上皮细胞系SRA01/04生物学特性的影响 [J]. 国际医药卫生导报, 2024, 30(9): 1478-1485.

Li Shiyi, Wang Kang, Huang Ju, Zhang Ao, Zhang Peipei, Xie Yingbin.

Effects of HSYA on biological characteristics of human lens epithelial cell line SRA01/04 [J]. International Medicine and Health Guidance News, 2024, 30(9): 1478-1485.

参考文献

[1] Das N, Shams A, Khan B, et al. Effects of neodymium-doped yttrium aluminium garnet (Nd:YAG) laser capsulotomy on visual outcomes from a lower-middle income country[J].Cureus,2021,13(9):e17895.DOI:10.7759/cureus.17895.
[2] Jiang M, Zhou LY, Xu N, et al. Hydroxysafflor yellow a inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways[J].Thorac Cancer,2019,10(6):1319-1333.DOI:10.1111/1759-7714.13019.
[3] Jin M, Wu Y, Wang L, et al. Hydroxysafflor yellow a attenuates bleomycin-induced pulmonary fibrosis in mice[J].Phytother Res,2016,30(4):577-587.DOI:10.1002/ptr.5560.
[4] Cong P, Huang G, Zhao Y, et al. Hydroxysafflor yellow a mitigates myocardial fibrosis induced by isoproterenol and angiotensin Ⅱ[J].Am J Transl Res,2022,14(12):8588-8598.
[5] Hu N, Duan J, Li H, et al. Hydroxysafflor yellow a ameliorates renal fibrosis by suppressing TGF-β1-induced epithelial-to-mesenchymal transition[J].PLoS One,2016,11(4):e0153409.DOI:10.1371/journal.pone.0153409.
[6] 刘阳,张天资. 红花黄色素在眼科领域中应用的研究进展[J]. 中国现代医药杂志,2022,24(4):101-104.DOI:10.3969/j.issn.1672-9463.2022.04.024.
[7] 许静,蔡小军. 羟基红花黄色素A抗晶状体氧化损伤的实验研究[J]. 眼科新进展,2008,28(3):190-194.DOI:10.3969/j.issn.1003-5141.2008.03.008.
[8] Fișuș AD, Findl O. Capsular fibrosis: a review of prevention methods and management[J].Eye (Lond),2020,34(2):256-262.DOI:10.1038/s41433-019-0723-5.
[9] Wu S, Tong N, Pan L, et al. Retrospective analyses of potential risk factors for posterior capsule opacification after cataract surgery[J].J Ophthalmol,2018,2018:9089285.DOI:10.1155/2018/9089285.
[10] Jiang J, Shihan MH, Wang Y, et al. Lens epithelial cells initiate an inflammatory response following cataract surgery[J].Invest Ophthalmol Vis Sci,2018,59(12):4986-4997.DOI:10.1167/iovs.18-25067.
[11] Wertheimer C, Liegl R, Kernt M, et al. EGFR-blockade with erlotinib reduces EGF and TGF-β2 expression and the actin-cytoskeleton which influences different aspects of cellular migration in lens epithelial cells[J].Curr Eye Res,2014,39(10):1000-1012.DOI:10.3109/02713683. 2014.888453.
[12] 金海鹰,郭海科. 细胞因子在后囊混浊形成中的作用[J]. 国外医学(眼科学分册),2000(3):154-159.
[13] Kampmeier J, Baldysiak-Figiel A, de Jong-Hesse Y, et al. Effect of growth factors on proliferation and expression of growth factor receptors in a human lens epithelial cell line[J].J Cataract Refract Surg,2006,32(3):510-514.DOI:10.1016/j.jcrs.2005.08.063.
[14] Majima K. Human lens epithelial cells proliferate in response to exogenous EGF and have EGF and EGF receptor[J].Ophthalmic Res,1995,27(6):356-365.DOI:10.1159/000267748.
[15] 胡艳红,祁明信,黄秀榕. 重组人表皮生长因子对牛品状体上皮细胞增殖的影响[J]. 眼科新进展,2007,27(10):732-734.DOI:10.3969/j.issn.1003-5141.2007.10.004.
[16] Wertheimer C, Liegl R, Kernt M, et al. EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification[J].Graefes Arch Clin Exp Ophthalmol,2013,251(6):1529-1540.DOI:10.1007/s00417-013-2257-z.
[17] Jiang Q, Zhou C, Bi Z, et al. EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells[J].J Ocul Pharmacol Ther,2006,22(2):93-102.DOI:10.1089/jop.2006.22.93.
[18] Dong N, Xu B, Xu J. EGF-mediated overexpression of myc attenuates miR-26b by recruiting HDAC3 to induce epithelial-mesenchymal transition of lens epithelial cells[J].Biomed Res Int,2018,2018:7148023.DOI:10.1155/2018/7148023.
[19] Meselhy MR, Kadota S, Momose Y, et al. Two new quinochalcone yellow pigments from Carthamus tinctorius and Ca2+ antagonistic activity of tinctormine[J].Chem Pharm Bull (Tokyo),1993,41(10):1796-1802.DOI:10.1248/cpb.41.1796.
[20] Su D, Lv C. Hydroxysafflor yellow a inhibits the proliferation, migration, and invasion of colorectal cancer cells through the PPARγ/PTEN/Akt signaling pathway[J].Bioengineered,2021,12(2):11533-11543.DOI:10.1080/21655979.2021.2009965.
[21] Chen X, Wang Y, Zhang L, et al. Hydroxysafflor yellow a of carthamus tinctorius L., represses the malignant development of esophageal cancer cells via regulating NF-κB signaling pathway[J].Cell Biochem Biophys,2020,78(4):511-520.DOI:10.1007/s12013-020-00934-1.
[22] Zhu HJ, Wang LJ, Wang XQ, et al. Hydroxysafflor yellow a (HYSA) inhibited the proliferation and differentiation of 3T3-L1 preadipocytes[J].Cytotechnology,2015,67(5):885-892.DOI:10.1007/s10616-014-9783-3.
[23] Wang J, Wang J, Wang X, et al. Molecular mechanism of inhibition of the abnormal proliferation of human umbilical vein endothelial cells by hydroxysafflor-yellow A[J].Pharm Biol,2016,54(9):1800-1807.DOI:10.3109/13880209.2015.1129541.
[24] Yuan W, Yang D, Sun X, et al. Effects of hydroxysafflor yellow a on proliferation and collagen synthesis of rat vascular adventitial fibroblasts induced by angiotensin Ⅱ[J].Int J Clin Exp Pathol,2014,7(9):5772-5781.
[25] Liu S, Wang Y, Wen H, et al. Hydroxysafflor yellow a inhibits TNF-α-induced inflammation of human fetal lung fibroblasts via NF-κB signaling pathway[J].Evid Based Complement Alternat Med,2019,2019:4050327.DOI:10.1155/2019/4050327.
[26] Song Y, Long L, Zhang N, et al. Inhibitory effects of hydroxysafflor yellow a on PDGF‑BB‑induced proliferation and migration of vascular smooth muscle cells via mediating akt signaling[J].Mol Med Rep,2014,10(3):1555-1560.DOI:10.3892/mmr.2014.2336.
[27] Yang G, Zhou X, Chen T, et al. Hydroxysafflor yellow a inhibits lipopolysaccharide-induced proliferation and migration of vascular smooth muscle cells via toll-like receptor-4 pathway[J].Int J Clin Exp Med,2015,8(4):5295-5302.
[28] Li Y, Shi Y, Sun Y, et al. Restorative effects of hydroxysafflor yellow a on hepatic function in an experimental regression model of hepatic fibrosis induced by carbon tetrachloride[J].Mol Med Rep,2017,15(1):47-56.DOI:10.3892/mmr.2016.5965.
[29] Unwin N, Gan D, Whiting D. The IDF diabetes atlas: providing evidence, raising awareness and promoting action[J].Diabetes Res Clin Pract,2010,87(1):2-3.DOI:10.1016/j.diabres.2009.11.006.
[30] 甄栋钦,梁金凤,王海英,等. 红花黄色素滴眼液对大鼠光化学损伤后视网膜变性的保护作用[J]. 国际医药卫生导报,2014,20(18):2770-2774.DOI:10.3760/cma.j.issn.1007-1245.2014.18.002.
[31] 褚文丽,亢泽峰,陈水龄,等. 中药单体化合物抑制眼内新生血管的作用及其机制[J]. 中国中医眼科杂志,2019,29(2):166-169.DOI:10.13444/j.cnki.zgzyykzz.2019.02.024.
[32] Li L, Dong P, Hou C, et al. Hydroxysafflor yellow a (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats[J].J Ethnopharmacol,2016,186:224-233.DOI:10.1016/j.jep.2016.04.004.
[33] 胡亚茹,陈悦,王剑锋.后发性白内障药物和基因治疗的研究现状[J].牡丹江医学院学报,2022,43(6):152-155.DOI:10.13799/j.cnki.mdjyxyxb.2022.06.027.
[34] 扶乾芳,李诗怡,张培培,等. miR-181在眼科疾病中的研究进展[J]. 国际医药卫生导报,2022,28(23):3342-3345.DOI:10.3760/cma.j.issn.1007-1245.2022.23.021.